O Visão Enfernal volta e a REvolta contra a Enfermagem como arte continua. A sua afirmação como ciência voltará a tomar lugar neste blogue, centrando a sua essência na divulgação da mais recente evidência científica.
comentar
publicado por Visao ENFernal, em 29.10.08 às 11:04link do post | favorito

 

 

Uma equipa liderada por David Bundle conduziu ao desenvolvimento de um composto capaz de minimizar os efeitos nefastos do tratamento de infecções por E.coli. A administração de antibióticos com vista ao tratamento de infecções provocadas por E.coli “Shiga-like” (capazes de produzir toxinas semelhantes à Shigella dysenteriae) tornam o corpo susceptível, uma vez que a lise celular liberta toxinas capazes de lesar as células do rim e provocar falência renal e o síndrome hemolitico-urémico (lesão vascular renal por uma endotoxemia aguda).

 

O PolyBAIT é um composto capaz de inibir o efeito prejudicial dessas toxinas, sendo uma arma promissora no combate a este tipo de infecções quando a terapêutica antibacteriana não garantia segurança ao doente:

 

University of Alberta

– Express News

 

"If you give [the patient] antibiotics the bacteria die and burst open, spilling their toxins," said Bundle, cautioning that if the E. coli toxin invades the kidney, the result can be fatal.

But Bundle and his colleagues-Pavel Kitov and Glen Armstrong-have created a drug that lashes the E.coli bacteria to a naturally-occurring protein molecule, preventing the E.coli from making contact with kidney cells.

The drug that acts like a lasso is called Polybait.

"Think of Polybait as piece of sticky string that wraps around the interface between the protein and the toxin," he said. "The surface of the toxin that kills kidney cells is drawn tightly against the surface of the protein and neutralizes it."

The molecules are held together long enough to be transported to the liver and eventually eliminated from the body.

 

HealthDay.Com

The inhibitor -- called (S)-PolyBAIT -- protected mice against the effects of a dose of a toxin produced by E. coli, said study principal author David Bundle, a chemistry professor at the University of Alberta, and colleagues, Agence France Presse reported.

The researchers said the inhibitor offers a more promising approach than antibiotics alone.

 

"Because antibiotic therapy alone is not used in practice because of the increased toxin load that results from toxin released by killed bacteria, such dual therapy may be an attractive option for the most severe E. coli infections," the researchers wrote, AFP reported.

 

O estudo não se fica por aqui, prometendo maiores avanços com o desenvolvimento deste modelo de actuação:

 

Advancing Chemical Sciences

 

'You could also address this to cholera toxin,' agrees Bundle. And because clustering of receptors can trigger cell death, he adds, he also hopes that drugs which establish multiple interactions between receptors could target cancer cells. His team are already working on a treatment for myeloma, a cancer which affects immune cells.


http://www.healthday.com/Article.asp?AID=620737

http://www.rsc.org/chemistryworld/News/2008/October/28100801.asp

http://www.expressnews.ualberta.ca/article.cfm?id=9716

http://news.smh.com.au/world/study-shows-potential-advance-in-fighting-e-coli-20081028-5af0.html

http://pt.wikipedia.org/wiki/Escherichia_coli

http://www.cve.saude.sp.gov.br/htm/hidrica/Ecolinet.htm

http://cache.daylife.com/imageserve/06Wn0MZgEPbAS/610x.jpg

 


mais sobre mim
Outubro 2008
Dom
Seg
Ter
Qua
Qui
Sex
Sab

1
2
3
4

5
6
7
8
9
10
11

12
13
14
15
16
17
18

19
20
21
22
23
24
25

26
28
30
31


links
pesquisar
 
blogs SAPO
subscrever feeds